Lista de obras - Lukas Smolej - Dominio Público Uruguay

A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples

article

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.

artículo científico publicado en 2016

Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features ⬇️

artículo científico publicado el 1 de agosto de 2010

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.

artículo científico publicado en 2016

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.

artículo científico publicado en 2016

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

artículo científico publicado en 2013

Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy

artículo científico publicado en 2010

Efficacy of pneumococcal vaccination in chronic lymphocytic leukemia: should we rely on surrogate markers?

scientific article published on 31 January 2008

Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.

artículo científico publicado en 2007

Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease

scientific article published on 01 June 2008

External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score

artículo científico publicado en 2020

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

artículo científico publicado en 2015

Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?

artículo científico publicado en 2006

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2017

Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia

scientific article published on 03 August 2007

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.

artículo científico publicado en 2016

Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.

artículo científico publicado en 2011

Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: more data needed.

artículo científico publicado en 2007

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

artículo científico publicado en 2015

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.

artículo científico publicado en 2015

Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

artículo científico publicado en 2015

Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 1 de septiembre de 2012

Practical approach to management of chronic lymphocytic leukemia

artículo científico publicado en 2015

Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia

artículo científico publicado en 2014

Prothrombotic changes due to an increase in thyroid hormone levels.

artículo científico publicado en 2015

Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.

artículo científico publicado en 2011

Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.

artículo científico publicado en 2016

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

artículo científico publicado en 2012

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

artículo científico publicado en 2016

Role of angiogenesis in chronic lymphocytic leukemia

artículo científico publicado en 2006

Skipping a step or "impatientitis": what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?

artículo científico publicado en 2020

TEM ExosomeAnalyzer: a computer-assisted software tool for quantitative evaluation of extracellular vesicles in transmission electron microscopy images

article

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

artículo científico publicado en 2014

Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphom

scientific article published on 10 February 2015

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

artículo científico publicado en 2013

The prognostic role of CLLU1 in chronic lymphocytic leukaemia

artículo científico publicado en 2006

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia ⬇️

artículo científico publicado el 23 de mayo de 2012

Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.

artículo científico publicado en 2016

Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?

artículo científico publicado en 2008

Venous thromboembolism in patients with chronic lymphocytic leukemia.

artículo científico publicado en 2015

Why R-CHOP for first line treatment of chronic lymphocytic leukemia?

artículo científico publicado en 2007

Lista de obras de Lukas Smolej

A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.

Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features ⬇️

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy

Efficacy of pneumococcal vaccination in chronic lymphocytic leukemia: should we rely on surrogate markers?

Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia.

Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease

External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.

Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.

Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: more data needed.

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.

Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia ⬇️

Practical approach to management of chronic lymphocytic leukemia

Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia

Prothrombotic changes due to an increase in thyroid hormone levels.

Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.

Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Role of angiogenesis in chronic lymphocytic leukemia

Skipping a step or "impatientitis": what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?

TEM ExosomeAnalyzer: a computer-assisted software tool for quantitative evaluation of extracellular vesicles in transmission electron microscopy images

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphom

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

The prognostic role of CLLU1 in chronic lymphocytic leukaemia

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia ⬇️

Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.

Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?

Venous thromboembolism in patients with chronic lymphocytic leukemia.

Why R-CHOP for first line treatment of chronic lymphocytic leukemia?